The adult mammalian heart possesses only limited capacity for innate regeneration and the response to severe injury is dominated by the formation of scar tissue. Current therapy to replace damaged cardiac tissue is limited to cardiac transplantation and thus many patients suffer progressive decay in the heart's pumping capacity to the point of heart failure. Nanostructured systems have the potential to revolutionize both preventive and therapeutic approaches for treating cardiovascular disease. Here, we outline recent advancements in nanotechnology that could be exploited to overcome the major obstacles in the prevention of and therapy for heart disease. We also discuss emerging trends in nanotechnology affecting the cardiovascular field that may offer new hope for patients suffering massive heart attacks.
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bui, A. L., Horwich, T. B. & Fonarow, G. C. Epidemiology and risk profile of heart failure. Nat. Rev. Cardiol. 8, 30–41 (2011).
Johnson, N. B. et al. CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors—United States, 2005–2013. MMWR Surveill. Summ. 63, 3–27 (2014).
Thygesen, K., Alpert, J. S. & White, H. D. Universal definition of myocardial infarction. J. Am. Coll. Cardiol. 50, 2173–2195 (2007).
Cassar, A., Holmes, D. R. Jr., Rihal, C. S. & Gersh, B. J. Chronic coronary artery disease: diagnosis and management. Mayo Clin. Proc. 84, 1130–1146 (2009).
White, H. D. & Chew, D. P. Acute myocardial infarction. Lancet 372, 570–584 (2008).
Senyo, S. E. et al. Mammalian heart renewal by pre-existing cardiomyocytes. Nature 493, 433–436 (2013).
Ziaeian, B. & Fonarow, G. C. Epidemiology and aetiology of heart failure. Nat. Rev. Cardiol. 13, 368–378 (2016).
Dunlay, S. M. & Roger, V. L. Understanding the epidemic of heart failure: past, present, and future. Curr. Heart Fail. Rep. 11, 404–415 (2014).
Wijns, W. et al. Guidelines on myocardial revascularization. Eur. Heart J. 31, 2501–2555 (2010).
Libby, P., Ridker, P. M. & Maseri, A. Inflammation and atherosclerosis. Circulation 105, 1135–1143 (2002).
Nabel, E. G. & Braunwald, E. A tale of coronary artery disease and myocardial infarction. N. Engl. J. Med. 366, 54–63 (2012).
Libby, P., Ridker, P. M. & Hansson, G. K. Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317–325 (2011).
Begum, M. & Sharma, H. Scope of nanomedicine against coronary artery disease: a review. Eur. J. Pharm. Med. Res. 3, 635–641 (2016).
Mahmoudi, M. et al. Protein−nanoparticle interactions: opportunities and challenges. Chem. Rev. 111, 5610–5637 (2011).
Nahrendorf, M. et al. Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation 117, 379–387 (2008).
Mahmoudi, M., Serpooshan, V. & Laurent, S. Engineered nanoparticles for biomolecular imaging. Nanoscale 3, 3007–3026 (2011).
Sanz, J. & Fayad, Z. A. Imaging of atherosclerotic cardiovascular disease. Nature 451, 953–957 (2008).
Zanganeh, S. et al. Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues. Nat. Nanotech. 11, 986–994 (2016).
Lobatto, M. E., Fuster, V., Fayad, Z. A. & Mulder, W. J. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat. Rev. Drug Discov. 10, 835–852 (2011).
Korin, N. et al. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science 337, 738–742 (2012).
Fredman, G. et al. Targeted nanoparticles containing the proresolving peptide Ac2–26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci. Transl. Med. 7, 275ra220 (2015).
Kamaly, N. et al. Targeted interleukin-10 nanotherapeutics developed with a microfluidic chip enhance resolution of inflammation in advanced atherosclerosis. ACS Nano 10, 5280–5292 (2016).
Kamaly, N. et al. Development and in vivo efficacy of targeted polymeric inflammation-resolving nanoparticles. Proc. Natl Acad. Sci. USA 110, 6506–6511 (2013).
Kamaly, N., He, J. C., Ausiello, D. A. & Farokhzad, O. C. Nanomedicines for renal disease: current status and future applications. Nat. Rev. Nephrol. 12, 738–753 (2016).
Duivenvoorden, R. et al. A statin-loaded reconstituted high-density lipoprotein nanoparticle inhibits atherosclerotic plaque inflammation. Nat. Commun. 5, 3531 (2014).
Chan, J. M. et al. Spatiotemporal controlled delivery of nanoparticles to injured vasculature. Proc. Natl Acad. Sci. USA 107, 2213–2218 (2010).
Chnari, E., Nikitczuk, J. S., Wang, J., Uhrich, K. E. & Moghe, P. V. Engineered polymeric nanoparticles for receptor-targeted blockage of oxidized low density lipoprotein uptake and atherogenesis in macrophages. Biomacromolecules 7, 1796–1805 (2006).
Lewis, D. R. et al. Sugar-based amphiphilic nanoparticles arrest atherosclerosis in vivo. Proc. Natl Acad. Sci. USA 112, 2693–2698 (2015).
Tomasini, M. D., Zablocki, K., Petersen, L. K., Moghe, P. V. & Tomassone, M. S. Coarse grained molecular dynamics of engineered macromolecules for the inhibition of oxidized low-density lipoprotein uptake by macrophage scavenger receptors. Biomacromolecules 14, 2499–2509 (2013).
Monopoli, M. P., Åberg, C., Salvati, A. & Dawson, K. A. Biomolecular coronas provide the biological identity of nanosized materials. Nat. Nanotech. 7, 779–786 (2012).
Mahmoudi, M. Protein corona: The golden gate to clinical applications of nanoparticles. Int. J. Biochem. Cell Biol. 75, 141–142 (2016).
Caracciolo, G., Farokhzad, O. C. & Mahmoudi, M. Biological identity of nanoparticles in vivo: clinical implications of the protein corona. Trends Biotechnol. 35, 257–264 (2017).
Salvati, A. et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotech. 7, 779–786 (2012).
Mirshafiee, V., Mahmoudi, M., Lou, K., Cheng, J. & Kraft, M. L. Protein corona significantly reduces active targeting yield. Chem. Commun. 49, 2557–2559 (2013).
Behzadi, S. et al. Protein corona change the drug release profile of nanocarriers: the “overlooked” factor at the nanobio interface. Colloids Surf. B 123, 143–149 (2014).
Moyano, D. F. et al. Fabrication of corona-free nanoparticles with tunable hydrophobicity. ACS Nano 8, 6748–6755 (2014).
Mirshafiee, V., Kim, R., Park, S., Mahmoudi, M. & Kraft, M. L. Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. Biomaterials 75, 295–304 (2016).
Deng, Z. J., Liang, M., Monteiro, M., Toth, I. & Minchin, R. F. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat. Nanotech. 6, 39–44 (2011).
Behfar, A., Crespo-Diaz, R., Terzic, A. & Gersh, B. J. Cell therapy for cardiac repair—lessons from clinical trials. Nat. Rev. Cardiol. 11, 232–246 (2014).
Nguyen, P. K., Rhee, J. W. & Wu, J. C. Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review. JAMA Cardiol. 1, 831–841 (2016).
Burridge, P. W., Keller, G., Gold, J. D. & Wu, J. C. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 10, 16–28 (2012).
Ranganath, S. H., Levy, O., Inamdar, M. S. & Karp, J. M. Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease. Cell Stem Cell 10, 244–258 (2012).
Nguyen, P. K., Neofytou, E., Rhee, J.-W. & Wu, J. C. Potential strategies to address the major clinical barriers facing stem cell regenerative therapy for cardiovascular disease: a review. JAMA Cardiol. 1, 953–962 (2016).
Mahmoudi, M. et al. Novel MRI contrast agent from magnetotactic bacteria enables in vivo tracking of iPSC-derived cardiomyocytes. Sci. Rep. 6, 26960 (2016).
Chong, J. J. et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510, 273–277 (2014).
Riegler, J. et al. Comparison of magnetic resonance imaging and serum biomarkers for detection of human pluripotent stem cell-derived teratomas. Stem Cell Rep. 6, 176–187 (2016).
Burridge, P. W. et al. Chemically defined generation of human cardiomyocytes. Nat. Methods 11, 855–860 (2014).
Cheng, K. et al. Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting. Nat. Commun. 5, 4880 (2014).
Shiba, Y. et al. Human ES-cell-derived cardiomyocytes electrically couple and suppress arrhythmias in injured hearts. Nature 489, 322–325 (2012).
Kawamura, M. et al. Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation 126, S29–S37 (2012).
Laflamme, M. A. & Murry, C. E. Heart regeneration. Nature 473, 326–335 (2011).
Mirotsou, M. et al. Secreted frizzled related protein 2 (Sfrp2) is the key Akt-mesenchymal stem cell-released paracrine factor mediating myocardial survival and repair. Proc. Natl Acad. Sci. USA 104, 1643–1648 (2007).
Han, J. et al. Iron oxide nanoparticle-mediated development of cellular gap junction crosstalk to improve mesenchymal stem cells' therapeutic efficacy for myocardial infarction. ACS Nano 9, 2805–2819 (2015).
Vandergriff, A. C. et al. Magnetic targeting of cardiosphere-derived stem cells with ferumoxytol nanoparticles for treating rats with myocardial infarction. Biomaterials 35, 8528–8539 (2014).
Xu, C. et al. Tracking mesenchymal stem cells with iron oxide nanoparticle loaded poly (lactide-co-glycolide) microparticles. Nano Lett. 12, 4131–4139 (2012).
Yang, X. Magnetic Resonance Imaging of Stem Cell Applications (Nova Science, 2015).
Mahmoudi, M., Bertrand, N., Zope, H. & Farokhzad, O. Emerging understanding of the nano-bio interface in nanomedicin. Nano Today 11, 817–832 (2016).
Chen, I. Y. et al. Comparison of optical bioluminescence reporter gene and superparamagnetic iron oxide MR contrast agent as cell markers for noninvasive imaging of cardiac cell transplantation. Mol. Imaging Biol. 11, 178–187 (2009).
Terrovitis, J. et al. Magnetic resonance imaging overestimates ferumoxide-labeled stem cell survival after transplantation in the heart. Circulation 117, 1555–1562 (2008).
Nguyen, P. K., Riegler, J. & Wu, J. C. Stem cell imaging: from bench to bedside. Cell Stem Cell 14, 431–444 (2014).
Takahama, H. et al. Liposomal amiodarone augments anti-arrhythmic effects and reduces hemodynamic adverse effects in an ischemia/reperfusion rat model. Cardiovasc. Drugs Ther. 27, 125–132 (2013).
Ewer, M. S. & Ewer, S. M. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know. Nat. Rev. Cardiol. 7, 564–575 (2010).
Burridge, P. et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat. Med. 22, 547–556 (2016).
Louch, W. E., Sheehan, K. A. & Wolska, B. M. Methods in cardiomyocyte isolation, culture, and gene transfer. J. Mol. Cell. Cardiol. 51, 288–298 (2011).
Yang, X., Pabon, L. & Murry, C. E. Engineering adolescence maturation of human pluripotent stem cell–derived cardiomyocytes. Circ. Res. 114, 511–523 (2014).
Kattman, S. J. et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 8, 228–240 (2011).
Sharma, A. et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci. Transl. Med. 9, eaaf2584 (2017).
Wei, K. et al. Epicardial FSTL1 reconstitution regenerates the adult mammalian heart. Nature 525, 479–485 (2015).
Ribeiro, A. J. et al. Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness. Proc. Natl Acad. Sci. USA 112, 12705–12710 (2015).
Sayed, N., Liu, C. & Wu, J. C. Translation of human-induced pluripotent stem cells: from clinical trial in a dish to precision medicine. J. Am. Coll. Cardiol. 67, 2161–2176 (2016).
O'Cearbhaill, E. D., Ng, K. S. & Karp, J. Emerging medical devices for minimally invasive cell therapy. Mayo Clin. Proc. 89, 259–273 (2014).
Wang, G. et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat. Med. 20, 616–623 (2014).
Yang, H. S. et al. Electroconductive nanopatterned substrates for enhanced myogenic differentiation and maturation. Adv. Healthcare Mater. 5, 137–145 (2016).
Wang, P.-Y., Yu, J., Lin, J.-H. & Tsai, W.-B. Modulation of alignment, elongation and contraction of cardiomyocytes through a combination of nanotopography and rigidity of substrates. Acta Biomater. 7, 3285–3293 (2011).
Macadangdang, J. et al. Nanopatterned human iPSC-based model of a dystrophin-null cardiomyopathic phenotype. Cell. Mol. Bioeng. 8, 320–332 (2015).
Carson, D. et al. Nanotopography-induced structural anisotropy and sarcomere development in human cardiomyocytes derived from induced pluripotent stem cells. ACS Appl. Mater. Interfaces 8, 21923–21932 (2016).
French, A. et al. Enabling consistency in pluripotent stem cell-derived products for research and development and clinical applications through material standards. Stem Cells Transl. Med. 4, 217–223 (2015).
Laflamme, M. A. et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 25, 1015–1024 (2007).
Mashinchian, O. et al. Regulation of stem cell fate by nanomaterial substrates. Nanomedicine 10, 829–847 (2015).
Mahmoudi, M. et al. Cell-imprinted substrates direct the fate of stem cells. ACS Nano 7, 8379–8384 (2013).
Mashinchian, O. et al. Cell-imprinted substrates act as an artificial niche for skin regeneration. ACS Appl. Mater. Interfaces 6, 13280–13292 (2014).
Bonakdar, S. et al. Cell-imprinted substrates modulate differentiation, redifferentiation, and transdifferentiation. ACS Appl. Mater. Interfaces 8, 13777–13784 (2016).
Wekerle, T. & Grinyó, J. M. Belatacept: from rational design to clinical application. Transpl. Int. 25, 139–150 (2012).
Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
Rong, Z. et al. An effective approach to prevent immune rejection of human ESC-derived allografts. Cell Stem Cell 14, 121–130 (2014).
Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase. Nat. Med. 9, 1269–1274 (2003).
Evans, C. W., Iyer, K. S. & Hool, L. C. The potential for nanotechnology to improve delivery of therapy to the acute ischemic heart. Nanomedicine 11, 817–832 (2016).
Heusch, G. et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet 383, 1933–1943 (2014).
Dvir, T. et al. Nanoparticles targeting the infarcted heart. Nano Lett. 11, 4411–4414 (2011).
Matsumura, Y. & Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387–6392 (1986).
Gerlowski, L. E. & Jain, R. K. Microvascular permeability of normal and neoplastic tissues. Microvasc. Res. 31, 288–305 (1986).
Bertrand, N., Wu, J., Xu, X., Kamaly, N. & Farokhzad, O. C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Delivery Rev. 66, 2–25 (2014).
Maeda, H. Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity. Adv. Drug Delivery Rev. 91, 3–6 (2015).
Shi, J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17, 20–37 (2017).
Hardy, N. et al. Nanoparticle-mediated dual delivery of an antioxidant and a peptide against the L-Type Ca2+ channel enables simultaneous reduction of cardiac ischemia-reperfusion injury. ACS Nano 9, 279–289 (2014).
Leuschner, F. et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29, 1005–1010 (2011).
Force, T., Krause, D. S. & Van Etten, R. A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7, 332–344 (2007).
Yeh, E. T. H. et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109, 3122–3131 (2004).
Nasr, M., Nafee, N., Saad, H. & Kazem, A. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice. Eur. J. Pharm. Biopharm. 88, 216–225 (2014).
Setyawati, M. et al. Titanium dioxide nanomaterials cause endothelial cell leakiness by disrupting the homophilic interaction of VE–cadherin. Nat. Commun. 4, 1673 (2013).
Smith, I., Liu, X., Smith, L. & Ma, P. Nanostructured polymer scaffolds for tissue engineering and regenerative medicine. Interdiscip. Rev. Nanomed. Nanobiotechnol. 1, 226–236 (2009).
Dvir, T., Timko, B. P., Kohane, D. S. & Langer, R. Nanotechnological strategies for engineering complex tissues. Nat. Nanotech. 6, 13–22 (2011).
Patel, D. N. & Bailey, S. R. Nanotechnology in cardiovascular medicine. Catheter. Cardiovasc. Interv. 69, 643–654 (2007).
Iverson, N., Plourde, N., Chnari, E., Nackman, G. B. & Moghe, P. V. Convergence of nanotechnology and cardiovascular medicine. BioDrugs 22, 1–10 (2008).
Riegler, J. et al. Human engineered heart muscles engraft and survive long term in a rodent myocardial infarction model. Circ. Res. 117, 720–730 (2015).
Serpooshan, V. et al. The effect of bioengineered acellular collagen patch on cardiac remodeling and ventricular function post myocardial infarction. Biomaterials 34, 9048–9055 (2013).
Hasan, A. et al. Injectable hydrogels for cardiac tissue repair after myocardial infarction. Adv. Sci. 2, 1500122 (2015).
Engelmayr, G. C. et al. Accordion-like honeycombs for tissue engineering of cardiac anisotropy. Nat. Mater. 7, 1003–1010 (2008).
Souza, G. R. et al. Three-dimensional tissue culture based on magnetic cell levitation. Nat. Nanotech. 5, 291–296 (2010).
Dvir, T. et al. Nanowired three-dimensional cardiac patches. Nat. Nanotech. 6, 720–725 (2011).
Feiner, R. et al. Engineered hybrid cardiac patches with multifunctional electronics for online monitoring and regulation of tissue function. Nat. Mater. 15, 679–85 (2016).
Bursac, N., Loo, Y., Leong, K. & Tung, L. Novel anisotropic engineered cardiac tissues: studies of electrical propagation. Biochem. Biophys. Res. Commun. 361, 847–853 (2007).
Timko, B. P., Cohen-Karni, T., Qing, Q., Tian, B. & Lieber, C. M. Design and implementation of functional nanoelectronic interfaces with biomolecules, cells, and tissue using nanowire device arrays. IEEE Trans. Nanotechnol. 9, 269–280 (2010).
Tian, B. et al. Three-dimensional, flexible nanoscale field-effect transistors as localized bioprobes. Science 329, 830–834 (2010).
Miura, M. et al. Effect of nonuniform muscle contraction on sustainability and frequency of triggered arrhythmias in rat cardiac muscle. Circulation 121, 2711–2717 (2010).
Liau, B., Zhang, D. & Bursac, N. Functional cardiac tissue engineering. Regen. Med. 7, 187–206 (2012).
Tzatzalos, E., Abilez, O. J., Shukla, P. & Wu, J. C. Engineered heart tissues and induced pluripotent stem cells: macro-and microstructures for disease modeling, drug screening, and translational studies. Adv. Drug Delivery Rev. 96, 234–244 (2016).
Burdick, J. A., Mauck, R. L., Gorman, J. H. & Gorman, R. C. Acellular biomaterials: an evolving alternative to cell-based therapies. Sci. Transl. Med. 5, 176ps4 (2013).
Baker, B. M., Handorf, A. M., Ionescu, L. C., Li, W.-J. & Mauck, R. L. New directions in nanofibrous scaffolds for soft tissue engineering and regeneration. Expert Rev. Med. Devices 6, 515–532 (2009).
Lee, J. W. 3D nanoprinting technologies for tissue engineering applications. J. Nanomater. 2015, 213521 (2015).
Serpooshan, V., Mahmoudi, M., Hu, D. A., Hu, J. B. & Wu, S. M. Bioengineering cardiac constructs using 3D printing. J. 3D Printing Med. 1, 123–139 (2017).
Giannopoulos, A. A. et al. Applications of 3D printing in cardiovascular diseases. Nat. Rev. Cardiol. 13, 701–718 (2016).
Dalton, P. D., Joergensen, N. T., Groll, J. & Moeller, M. Patterned melt electrospun substrates for tissue engineering. Biomed. Mater. 3, 034109 (2008).
Chaudhury, K., Kumar, V., Kandasamy, J. & RoyChoudhury, S. Regenerative nanomedicine: current perspectives and future directions. Int. J. Nanomed. 9, 4153–4167 (2014).
Kamaly, N., Xiao, Z., Valencia, P. M., Radovic-Moreno, A. F. & Farokhzad, O. C. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem. Soc. Rev. 41, 4153–4167 (2012).
Behzadi, S. et al. Cellular uptake of nanoparticles: journey inside the cell. Chem. Soc. Rev. 46, 4218–4244 (2017).
Bertrand, N. et al. Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics. Nat. Commun. (in the press).
Mahmoudi, M. et al. Temperature: the “ignored” factor at the nanobio interface. ACS Nano 7, 6555–6562 (2013).
Mahmoudi, M. et al. Variation of protein corona composition of gold nanoparticles following plasmonic heating. Nano Lett. 14, 6–12 (2014).
Monopoli, M. P. et al. Physical−chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 133, 2525–2534 (2011).
Hajipour, M. J., Laurent, S., Aghaie, A., Rezaee, F. & Mahmoudi, M. Personalized protein coronas: a “key” factor at the nanobiointerface. Biomater. Sci. 2, 1210–1221 (2014).
Corbo, C., Molinaro, R., Tabatabaei, M., Farokhzad, O. C. & Mahmoudi, M. Personalized protein corona on nanoparticles and its clinical implications. Biomater. Sci. 5, 378–387 (2017).
Walkey, C. D. et al. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano 8, 2439–2455 (2014).
Bigdeli, A. et al. Exploring cellular interactions of liposomes using protein corona fingerprints and physicochemical properties. ACS Nano 10, 3723–3737 (2016).
Sharifi, S. et al. Toxicity of nanomaterials. Chem. Soc. Rev. 41, 2323–2343 (2012).
Buzea, C., Pacheco, I. I. & Robbie, K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases 2, MR17–MR71 (2007).
Bostan, H. B. et al. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Life Sci. 165, 91–99 (2016).
Fleischer, S., Feiner, R. & Dvir, T. Cutting-edge platforms in cardiac tissue engineering. Curr. Opin. Biotechnol. 47, 23–29 (2017).
Hrkach, J. et al. Cardiotoxicity of nano-particles. Sci. Transl. Med. 4, 128ra139 (2012).
Gu, F. et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl Acad. Sci. USA 105, 2586–2591 (2008).
Kim, Y. et al. Mass production and size control of lipid–polymer hybrid nanoparticles through controlled microvortices. Nano Lett. 12, 3587–3591 (2012).
Xu, J. et al. Future of the particle replication in nonwetting templates (PRINT) technology. Angew. Chem. Int. Ed. 52, 6580–6589 (2013).
Hajipour, M. J. et al. Personalized disease-specific protein corona influences the therapeutic impact of graphene oxide. Nanoscale 7, 8978–8994 (2015).
Smith, A. S. T., Macadangdang, J., Leung, W., Laflamme, M. A. & Kim, D.-H. Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and drug screening. Biotechnol. Adv. 35, 77–94 (2017).
Tenzer, S. et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotech. 8, 772–781 (2013).
Pozzi, D. et al. The biomolecular corona of nanoparticles in circulating biological media. Nanoscale 7, 13958–13966 (2015).
Ott, H. C. et al. Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat. Med. 14, 213–221 (2008).
Tian, B. et al. Macroporous nanowire nanoelectronic scaffolds for synthetic tissues. Nat. Mater. 11, 986–994 (2012).
Sooppan, R. et al. In vivo anastomosis and perfusion of a three-dimensionally-printed construct containing microchannel networks. Tissue Eng. Part C Methods 22, 1–7 (2015).
Murphy, S. V. & Atala, A. 3D bioprinting of tissues and organs. Nat. Biotechnol. 32, 773–785 (2014).
This work was supported by the US National Institutes of Health grants HL127464-01A1 (O.C.F.), EB015419 (O.C.F.) and HL133272 (J.C.W.), and Department of Defense grant PC140318 (O.C.F.).
R.L. and O.C.F. declare financial interests in Selecta Biosciences, Tarveda Therapeutics and Placon Therapeutics. R.L. declares financial interests in Moderna.
About this article
Cite this article
Mahmoudi, M., Yu, M., Serpooshan, V. et al. Multiscale technologies for treatment of ischemic cardiomyopathy. Nature Nanotech 12, 845–855 (2017). https://doi.org/10.1038/nnano.2017.167
Phagocytosis of polymeric nanoparticles aided activation of macrophages to increase atherosclerotic plaques in ApoE−/− mice
Journal of Nanobiotechnology (2021)
A carbon nanotubes based in situ multifunctional power assist system for restoring failed heart function
BMC Biomedical Engineering (2021)
Nature Communications (2021)
Stem Cell Reviews and Reports (2021)
Injectable collagen scaffold promotes swine myocardial infarction recovery by long-term local retention of transplanted human umbilical cord mesenchymal stem cells
Science China Life Sciences (2021)